Aurigene Pharmaceutical Services Limited (APSL) is an integrated partner for global pharma companies. It covers the entire value chain for new therapeutics, from drug discovery, clinical research, and development to manufacturing APIs and formulation at commercial scales. It has development laboratories from discovery to clinical phase III for New Chemical and Biological Entities (NCEs/NBEs) and cGMP manufacturing facilities in the UK, Mexico, USA, and India. The technology platforms include cytotoxic APIs, carbohydrates, steroids, PEG derivatives, prostaglandins, peptides, and oligonucleotides. Large molecule discovery services include ADC, MAB, mRNA, CART-T as well as development services in MAB and protein therapeutics.